KR20230058014A - 급성 호흡곤란 증후군(arda) 및 코로나바이러스로 인한 염증 장애를 치료하기 위한 조성물 및 방법 - Google Patents

급성 호흡곤란 증후군(arda) 및 코로나바이러스로 인한 염증 장애를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230058014A
KR20230058014A KR1020227045667A KR20227045667A KR20230058014A KR 20230058014 A KR20230058014 A KR 20230058014A KR 1020227045667 A KR1020227045667 A KR 1020227045667A KR 20227045667 A KR20227045667 A KR 20227045667A KR 20230058014 A KR20230058014 A KR 20230058014A
Authority
KR
South Korea
Prior art keywords
sars
drug
inflammatory
agent
ards
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227045667A
Other languages
English (en)
Korean (ko)
Inventor
리처드 엘. 창
벤 와이. 창
Original Assignee
포르-메드, 인코포레이티드
리처드 엘. 창
벤 와이. 창
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포르-메드, 인코포레이티드, 리처드 엘. 창, 벤 와이. 창 filed Critical 포르-메드, 인코포레이티드
Publication of KR20230058014A publication Critical patent/KR20230058014A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227045667A 2020-05-28 2021-05-27 급성 호흡곤란 증후군(arda) 및 코로나바이러스로 인한 염증 장애를 치료하기 위한 조성물 및 방법 Pending KR20230058014A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031551P 2020-05-28 2020-05-28
US63/031,551 2020-05-28
PCT/US2021/034494 WO2021243007A2 (en) 2020-05-28 2021-05-27 Compositions and methods for treating acute respiratory distress syndrome (ards) and inflammatory disorders caused by coronaviruses and other respiratory pathogens or agents that mediate pulmonary injury, inflammation or acute respiratory distress, and related compositions and methods for treating and preventing human sars coronavirus infection, covid-19 disease and related symptoms

Publications (1)

Publication Number Publication Date
KR20230058014A true KR20230058014A (ko) 2023-05-02

Family

ID=78722786

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045667A Pending KR20230058014A (ko) 2020-05-28 2021-05-27 급성 호흡곤란 증후군(arda) 및 코로나바이러스로 인한 염증 장애를 치료하기 위한 조성물 및 방법

Country Status (12)

Country Link
US (3) US20230248684A1 (cg-RX-API-DMAC7.html)
EP (1) EP4304570A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023528804A (cg-RX-API-DMAC7.html)
KR (1) KR20230058014A (cg-RX-API-DMAC7.html)
CN (1) CN117015375A (cg-RX-API-DMAC7.html)
AU (1) AU2021281257A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024226A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180577A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003348A1 (cg-RX-API-DMAC7.html)
IL (1) IL298593B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022014958A (cg-RX-API-DMAC7.html)
WO (1) WO2021243007A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2021207497A1 (en) * 2020-04-08 2021-10-14 Arizona Board Of Regents On Behalf Of Arizona State University Covid-19 inflammatory cytokine storm treatment
US20230071393A1 (en) * 2020-04-16 2023-03-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Matrix bound vesicles (mbv) for treatment of acute respiratory distress syndrome
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist
CN115252760B (zh) * 2022-03-30 2024-05-31 厦门大学 一种广谱抗冠状病毒的制剂及其制备方法
WO2025029797A1 (en) * 2023-08-01 2025-02-06 Incelldx, Inc. Methods of assigning a covid pathological type and compositions for practicing the same, and methods of treating a subject for chronic covid-19
CN117304031A (zh) * 2023-09-05 2023-12-29 深圳大学 一种铁苋菜二萜类化合物、铁苋菜提取物及其在制备具有抗氧化和/或抗炎作用的产品中的应用
CN117414438B (zh) * 2023-11-01 2025-10-17 大连医科大学附属第一医院 一种靶向m1型巨噬细胞的多肽偶联药物及其应用
CN117919385B (zh) * 2024-02-05 2024-10-18 中国医学科学院医学实验动物研究所 IL-37在MERS-CoV感染疾病的治疗中的应用
CN121490288A (zh) * 2025-11-21 2026-02-10 中山大学附属第三医院 一种用于急性呼吸窘迫综合征的肺部交感神经局部光遗传激活系统及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
US20030109486A1 (en) * 2001-10-31 2003-06-12 Eliezer Rapaport Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
ES2464459T3 (es) * 2008-06-25 2014-06-02 H. Lundbeck A/S Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
KR101374760B1 (ko) * 2011-10-26 2014-03-17 한국생명공학연구원 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
JP6977206B2 (ja) * 2016-03-31 2021-12-08 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same

Also Published As

Publication number Publication date
CL2022003348A1 (es) 2023-12-01
JP2023528804A (ja) 2023-07-06
BR112022024226A2 (pt) 2023-01-31
CA3180577A1 (en) 2021-12-02
MX2022014958A (es) 2023-04-13
EP4304570A2 (en) 2024-01-17
AU2021281257A1 (en) 2023-02-02
CN117015375A (zh) 2023-11-07
US20240082202A1 (en) 2024-03-14
WO2021243007A2 (en) 2021-12-02
WO2021243007A3 (en) 2021-12-30
US20260041660A1 (en) 2026-02-12
IL298593A (en) 2023-01-01
EP4304570A4 (en) 2025-01-22
US20230248684A1 (en) 2023-08-10
IL298593B1 (en) 2026-06-01

Similar Documents

Publication Publication Date Title
US20260041660A1 (en) Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms
Perico et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Fodor et al. Endothelial dysfunction, inflammation, and oxidative stress in COVID‐19—mechanisms and therapeutic targets
Panahi et al. An overview on the treatments and prevention against COVID-19
Hosseini et al. Innate and adaptive immune responses against coronavirus
Clementi et al. Viral respiratory pathogens and lung injury
Lotfi et al. SARS‐CoV‐2: A comprehensive review from pathogenicity of the virus to clinical consequences
Bartoli et al. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs
Anand et al. Potential therapeutic targets and vaccine development for SARS-CoV-2/COVID-19 pandemic management: a review on the recent update
Canedo-Marroquin et al. SARS-CoV-2: immune response elicited by infection and development of vaccines and treatments
TW202144383A (zh) 冠狀病毒免疫原性組合物及其等之用途
Cancio et al. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies
WO2021161043A1 (en) Prevention and treatment of infections including those caused by coronavirus
Song et al. C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury
Lin et al. Coronavirus in human diseases: mechanisms and advances in clinical treatment
Leyfman et al. Potential immunotherapeutic targets for hypoxia due to COVI-Flu
Samaddar et al. Pathophysiology and potential therapeutic candidates for COVID-19: a poorly understood arena
Patel et al. The immunopathobiology of SARS-CoV-2 infection
US20230295281A1 (en) Natural antibodies in prophylaxis and therapy
WO2022140706A1 (en) Immune-regulatory li-key peptide vaccines for prophylaxis and long-term protection against sars-cov-2 infection and covid-19 disease
Dezfuli et al. Update on immunology of COVID-19 disease and potential strategy for controlling
Chukwuma et al. Mechanisms and potential therapeutic targets of hyperinflammatory responses in SARS-CoV-2
Lyubavina et al. Immunological approaches to the treatment of new coronavirus infection
JP2023529124A (ja) コロナウイルスワクチンコンストラクトおよびこれを作製し使用する方法
Mukerjee A brief review on the overview on immunology of COVID-19: current state of the research

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000